Page last updated: 2024-12-08
triperiden
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
triperiden: RN given refers to HCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 161077 |
| SCHEMBL ID | 7438611 |
| MeSH ID | M0135122 |
Synonyms (25)
| Synonym |
|---|
| 33068-73-4 |
| 4-(diphenylmethyloxy)-1-methylpiperidine methylbromide quaternary salt |
| 1-piperidinepropanol, alpha-phenyl-alpha-tricyclo(2.2.1.02,6)hept-3-yl-, hydrochloride (van) |
| norakin |
| piperidinium, 1,1-dimethyl-4-(diphenylmethoxy)-, bromide |
| p 260 |
| triperiden |
| 14617-17-5 |
| unii-36wj53288e |
| 36wj53288e , |
| n-methylpiperidyl-(4)-benzhydrylaether methylbromid quaternister |
| n-methylpiperidyl-(4)-benzhydrylaether methylbromid quaternistert [german] |
| triperiden hydrochloride |
| 1-piperidinepropanol, .alpha.-phenyl-.alpha.-tricyclo(2.2.1.02,6)hept-3-yl-, hydrochloride |
| triperiden hydrochloride [who-dd] |
| SCHEMBL7438611 |
| Q4463153 |
| 1-phenyl-3-(piperidin-1-yl)-1-(tricyclo[2.2.1.0~2,6~]heptan-3-yl)propan-1-ol--hydrogen chloride (1/1) |
| DTXSID20932778 |
| 1-phenyl-3-piperidin-1-yl-1-(3-tricyclo[2.2.1.02,6]heptanyl)propan-1-ol;hydrochloride |
| F83856 |
| MS-25355 |
| HY-145391 |
| CS-0372801 |
| AKOS040756837 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (69.23) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.34
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.34) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||